AbbVie Inc Valuation – March 2019 #ABBV

Company Profile (excerpt from Reuters): AbbVie Inc. (AbbVie), incorporated on April 10, 2012, is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.


Downloadable PDF version of this valuation:

ModernGraham Valuation of ABBV – March 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $118,154,226,149 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 0.98 Fail
3. Earnings Stability Positive EPS for 10 years prior Fail
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 363.28% Pass
6. Moderate PEmg Ratio PEmg < 20 15.46 Pass
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 -14.24 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 0.98 Fail
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 -119.05 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass


Stage 2: Determination of Intrinsic Value

EPSmg $5.18
MG Growth Estimate 15.00%
MG Value $199.51
Opinion Undervalued
MG Grade C
MG Value based on 3% Growth $75.14
MG Value based on 0% Growth $44.05
Market Implied Growth Rate 3.48%
Current Price $80.10
% of Intrinsic Value 40.15%

AbbVie Inc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, and the poor dividend history, and the high PB ratio. The Enterprising Investor has concerns regarding the level of debt relative to the current assets. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Undervalued after growing its EPSmg (normalized earnings) from $2.3 in 2015 to an estimated $5.18 for 2019. This level of demonstrated earnings growth outpaces the market’s implied estimate of 3.48% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value above the price.

At the time of valuation, further research into AbbVie Inc revealed the company was trading above its Graham Number of $0. The company pays a dividend of $3.59 per share, for a yield of 4.5%, putting it among the best dividend paying stocks today. Its PEmg (price over earnings per share – ModernGraham) was 15.46, which was below the industry average of 47.6, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-33.88.

AbbVie Inc receives an average overall rating in the ModernGraham grading system, scoring a C.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$33.88
Graham Number $0.00
PEmg 15.46
Current Ratio 0.98
PB Ratio -14.24
Current Dividend $3.59
Dividend Yield 4.48%
Number of Consecutive Years of Dividend Growth 6

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2018
Total Current Assets $16,945,000,000
Total Current Liabilities $17,239,000,000
Long-Term Debt $35,002,000,000
Total Assets $59,352,000,000
Intangible Assets $36,896,000,000
Total Liabilities $67,798,000,000
Shares Outstanding (Diluted Average) 1,501,000,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $8.56
Dec2018 $3.66
Dec2017 $3.30
Dec2016 $3.63
Dec2015 $3.13
Dec2014 $1.10
Dec2013 $2.56
Dec2012 $3.35

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $5.18
Dec2018 $3.32
Dec2017 $3.01
Dec2016 $2.83
Dec2015 $2.30
Dec2014 $1.72
Dec2013 $1.75
Dec2012 $1.12

Recommended Reading:

Other ModernGraham posts about the company

10 Best Dividend Paying Stocks for the Enterprising Investor – May 2018
AbbVie Inc Valuation – April 2018 $ABBV
10 Stocks for Using A Benjamin Graham Value Investing Strategy – January 2017
9 Best Stocks For Value Investors This Week – 7/23/16
AbbVie Inc Valuation – July 2016 $ABBV

Other ModernGraham posts about related companies

Allergan PLC Valuation – February 2019 $AGN
Incyte Corp Valuation – February 2019 $INCY
Regeneron Pharmaceuticals Inc Valuation – February 2019 $REGN
Alexion Pharmaceuticals Inc Valuation – February 2019 $ALXN
Vertex Pharmaceuticals Inc Valuation – February 2019 $VRTX
Perrigo Company Valuation – February 2019 $PRGO
Eli Lilly and Co Valuation – January 2019 $LLY
Zoetis Inc Valuation – January 2019 $ZTS
Gilead Sciences Inc Valuation – January 2019 $GILD
Pfizer Inc Valuation – November 2018 $PFE


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.